Nutrients act both directly and indirectly to modulate muscle protein accretion through changes in protein synthesis and degradation. For example, glucose, amino acids and fatty acids can all be metabolized to produce energy in the form of ATP that can be utilized for protein synthesis. In addition, amino acids are used directly for the synthesis of new proteins. Nutrients also regulate protein synthesis through activation of a signalling pathway involving the protein kinase, mTOR [mammalian TOR (target of rapamycin)]. Together with several regulatory proteins, mTOR forms a complex referred to as TORC1 (TOR complex 1). Because of its central role in controlling cell growth, TORC1 is an integral component of the mechanism through which nutrients modulate protein synthesis. Herein, the mechanism(s) through which nutrients, and in particular amino acids, regulate signalling through TORC1 will be discussed. In addition, downstream effectors of TORC1 action on mRNA translation will be briefly presented. Finally, a previously unrecognized effector of TORC1 signalling in regulating protein synthesis will be described.
Introduction
The increase in muscle protein synthesis that occurs in response to consumption of a complete meal by a fasted individual is a result not only of increased availability of the substrates used for synthesizing protein, i.e. amino acids, but also due to nutrient-and hormone-induced activation of intracellular signalling pathways that regulate mRNA translation. Arguably, one of the most important nutrientregulated signalling pathways in muscle involves a complex of proteins that includes the protein kinase referred to as mTOR [mammalian TOR (target of rapamycin)], raptor (regulatory associated protein of mTOR), Rheb (Ras homologue enriched in brain), PRAS40 (proline-rich Akt substrate 40) , LST8 (also known as GβL for G-protein β-like protein), and possibly other as yet unidentified proteins. Together, these proteins form the TORC1 (TOR complex 1; Figure 1 ). The purpose of the present paper is to briefly discuss the signalling pathway through which amino acids act to increase mTOR signalling as well as downstream effectors of mTOR action on mRNA translation.
The TORC1 complex
Raptor was one of the first regulatory proteins shown to be present in the TORC1 complex [1, 2] . It functions as Key words: eukaryotic initiation factor 4E (eIF4E), eukaryotic initiation factor 4E-binding protein-1 (4E-BP1), leucine, mammalian target of rapamycin (mTOR), S6 kinase 1 (S6K1), target of rapamycin complex 1 (TORC1). Abbreviations used: AMPK, AMP-activated protein kinase; BCH, 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid; eEF, eukaryotic elongation factor; eIF4E, eukaryotic initiation factor 4E; 4E-BP1, e1F 4E-binding protein-1; GEF, guanine-nucleotide-exchange factor; tRNAi Met , initiator methionine tRNA; TOR, target of rapamycin; mTOR, mammalian TOR; PA, phosphatidic acid; PI3K, phosphoinositide 3-kinase; PLD1, phospholipase D1; PRAS40, proline-rich Akt substrate 40; raptor, regulatory associated protein of mTOR; Rheb, Ras homologue enriched in brain; rpS6, S6 ribosomal protein; S6K1, S6 kinase 1; TORC1, TOR complex 1; TOS motif, TOR signalling motif; TSC2, tuberous sclerosis complex 2; Vps34, vacuolar protein sorting 34. 1 email skimball@psu.edu an adaptor protein that recruits substrates to TORC1 for phosphorylation. For example, raptor binds to a domain, referred to as the TOS motif (TOR signalling motif), present in the two best characterized TORC1 substrates, the ribosomal protein S6K1 (S6 kinase 1) and 4E-BP1 [eIF4E (eukaryotic initiation factor 4E)-binding protein-1], thereby targeting them for phosphorylation [3, 4] . The importance of raptor in substrate selection is emphasized by the finding that TORC2, in which raptor is replaced by a protein referred to as the rictor (rapamycin-insensitive companion of mTOR), does not phosphorylate either 4E-BP1 or S6K1, but instead phosphorylates Akt [also called PKB (protein kinase B)] and PKC (protein kinase C) [5] [6] [7] . mTOR protein kinase activity is also regulated by its interaction with Rheb [8] [9] [10] . Like other Ras homologues, Rheb binds to both GDP and GTP, and both the Rheb ᭹ GDP and Rheb ᭹ GTP complexes bind to mTOR. However, the two Rheb complexes have opposite effects on mTOR kinase activity. Thus Rheb ᭹ GTP acts to increase mTOR signalling, whereas Rheb ᭹ GDP acts to repress it [8, 9] . Although not a universal finding (e.g. [10] ), recent studies suggest that amino acids do not alter Rheb GTP loading, but instead, through an unknown mechanism, increase the binding of Rheb ᭹ GTP to mTOR [8, 9] .
Two recent studies [11, 12] report the identification of PRAS40 as a component of TORC1. Thus PRAS40 binds to both mTOR and raptor and acts to repress signalling through mTOR, possibly through a direct interaction with the mTOR protein kinase domain [11] . Interestingly, in HEK-293T cells [human embryonic kidney-293 cells expressing the large T-antigen of SV40 (simian virus 40)], leucine deprivation leads to an increase in the amount of PRAS40 associated with TORC1 and leucine re-addition to deprived cells results in a rapid (within 1 h) decrease in the amount of PRAS40 bound to TORC1 [11] . Thus leucine may increase signalling through TORC1 in part by modulating the binding of PRAS40 to mTOR and/or raptor.
Upstream of TORC1
Hormones, such as insulin and IGF-1 (insulin-like growth factor-1), activate mTOR through a signalling pathway involving the type 1 PI3K (phosphoinositide 3-kinase) and Akt ( Figure 2 ). Activated Akt phosphorylates at least three proteins that modulate TORC1 signalling including mTOR itself [13, 14] , PRAS40 [15] and the TSC2 (tuberous sclerosis complex 2) [16] [17] [18] . Of the three, phosphorylation of TSC2 by Akt is best characterized. TSC2 is a GTPase-activating protein for Rheb [19] [20] [21] . Phosphorylation of TSC2 on multiple residues by Akt leads to its inactivation, thereby increasing the proportion of Rheb complexed with GTP. Consequently, inhibition of TSC2 by Akt leads to an increase in mTOR signalling due to increased association of Rheb ᭹ GTP with mTOR. A second mechanism through which Akt may act to increase TORC1 signalling is through phosphorylation of PRAS40. Phosphorylation of PRAS40 by Akt leads to its dissociation from TORC1 and increased mTOR protein kinase activity [11] . However, the preponderance of evidence suggests that amino acids do not activate Akt, and therefore Aktmediated phosphorylation of either TSC2 or PRAS40 is unlikely to account for amino acid-induced mTOR activation.
Amino acid signalling to mTOR is also unlikely to be mediated by TSC2. This idea is supported by studies showing that amino acids modulate mTOR signalling in cells lacking TSC2 [10, 22] . Moreover, amino acid deprivation does not alter the proportion of Rheb in the active, GTP-bound form [9, 21] . Instead, recent studies have implicated the type III PI3K, Vps34 (vacuolar protein sorting 34), in the regulation of mTOR by amino acids [22, 23] . Unlike type I PI3Ks, Vps34 is not activated by insulin and does not activate Akt [23, 24] . Instead, Vps34 in a complex with the protein kinase Vps15 generates PI3P (phosphatidylinositol 3-phosphate) on endosomal membranes, resulting in recruitment of proteins containing FYVE or PX (Phox homology) domains to intracellular membranes [25] . In mammalian cells, siRNA (small interfering RNA) repression of either Vps34 or Vps15 reduces amino acid repletion-induced phosphorylation of the TORC1 substrate, S6K1 [22] . However, the mechanism through which amino acids might act to increase Vps34 signalling is unknown.
In addition to amino acids, other nutrients such as glucose and fatty acids also regulate TORC1 signalling. For example, in heart, fatty acids are potent activators of the TORC1 signalling pathway [26, 27] . Similarly, in the pancreatic β-cell line MIN6, increasing the glucose concentration in the culture medium results in activation of TORC1 [28] . In both examples, the activation of mTOR is a consequence of inhibition of a protein kinase referred to as AMPK (AMPactivated protein kinase). AMPK activity is regulated in part through changes in the AMP/ATP ratio, whereby increases in the ratio result in activation of the protein kinase [29] . In heart, increased fatty acid oxidation leads to a decrease in the AMP/ATP ratio, resulting in inhibition of AMPK. Interestingly, in glucose-and amino acid-deprived MIN6 cells, amino acid supplementation is as potent as glucose in increasing TORC1 signalling [28] . The stimulation of TORC1 activity engendered by amino acid supplementation is mimicked by addition of a combination of glutamine and either leucine or its non-metabolizable analogue, BCH [2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid] to the culture medium. In contrast, glutamine, leucine or BCH alone have little effect on TORC1 signalling. The authors conclude that the effect of the glutamine and leucine/BCH combination is due to leucine/BCH-induced activation of glutamate dehydrogenase that results in a decrease in the AMP/ATP ratio and subsequent repression of AMPK.
AMPK modulates TORC1 signalling through at least two independent mechanisms. In the first case, AMPK phosphorylates TSC2 on multiple residues, resulting in its activation [30] . In the second case, AMPK directly phosphorylates mTOR, an event that correlates with decreased mTOR activity [31] . Therefore nutrient-mediated inhibition of AMPK probably leads to mTOR activation both by repressing the activity of the mTOR inhibitor TSC2 as well as through decreased phosphorylation of mTOR itself on inhibitory residues.
Another important mechanism for enhancing signalling through TORC1 is through increase in PA (phosphatidic acid), for example, upon activation of PLD 1 (phospholipase D 1 ) or PLD 2 . PA binds directly to the mTOR FKBP12 (FK506-binding protein 12) ᭹ rapamycin-binding domain, leading to activation of mTOR kinase activity [32] . Signalling through TORC1 may also be stimulated through a direct interaction of TORC1 with PLD 2 , because PLD 2 , like 4E-BP1 and S6K1, contains a TOS motif that allows for its specific interaction with raptor [33] . Both wild-type PLD 2 and an inactive mutant interact with TORC1. However, only the active form of the enzyme, not the inactive mutant, promotes increased phosphorylation of 4E-BP1 and S6K1. Interestingly, activation of PLD may be an important mechanism for increasing TORC1 signalling in response to exercise. Thus mechanical stimulation of ex vivo muscle preparations leads to activation of PLD, increased PA accumulation, and increased TORC1 signalling [34] . A recent study suggests that PA may also bind to and activate S6K1 through an mTOR-independent mechanism [35] . Thus PA may lead to activation of some downstream mTOR effectors through both direct and indirect mechanisms.
Downstream of TORC1
Up-regulated nutrient signalling through TORC1 leads to increased phosphorylation of several proteins that play important roles in regulating the mRNA-binding step in translation initiation including S6K1 and 4E-BP1 [36] . Phosphorylation of S6K1 by mTOR represents a key step in its activation. S6K1 subsequently phosphorylates eIF4B [37, 38] and eEF2 (eukaryotic elongation factor 2) kinase [39] . Phosphorylation of 4E-BP1 by mTOR results in its release from the inactive 4E-BP1 ᭹ eIF4E complex, allowing the mRNA cap-binding protein eIF4E to associate with eIF4G and eIF4A to form the active eIF4F complex [36] . The activity of the eIF4F complex is further stimulated by its interaction with phosphorylated eIF4B, an activator of the RNA helicase activity of eIF4A. Depending on the cell type, amino acid-induced assembly of the eIF4F complex can lead to increased global rates of protein synthesis and also to changes in the selection of mRNAs for translation, thereby altering the pattern of gene expression at the protein level. For example, activation of TORC1 preferentially increases the translation of mRNAs encoding proteins such as eEF1A, eEF2 and many ribosomal proteins, thereby increasing the capacity of the cell to synthesize protein (see e.g. [40] ). Previously it was thought that the increase in translation of such mRNAs was due to S6K1-mediated phosphorylation of rpS6 (S6 ribosomal protein) [41] . However, more recent studies have shown that these mRNAs can be translationally regulated in cells lacking both S6K1 and S6K2 [42] as well as in cells and animals in which the wild-type gene encoding rpS6 is replaced with a mutant encoding a protein that cannot be phosphorylated by S6K1 [43] . Thus the rapamycin-sensitive increase in translation of mRNAs encoding proteins such as eEF1A and eIF2 must occur through an S6K1-independent mechanism. However, the identity of the putative regulator remains elusive.
Recent studies have identified a previously unrecognized effector of TORC1 signalling, the ε-subunit of eIF2B (eIF2Bε) [48] . eIF2B is a GEF (guanine-nucleotide-exchange factor) for a second translation factor, eIF2 [44] . During initiation, the eIF2 ᭹ GTP complex binds tRNA i Met (initiator methionine tRNA) and the resulting ternary complex binds to the 40S ribosomal subunit. During a later step in initiation, the GTP bound to eIF2 is hydrolysed to GDP, and the eIF2 ᭹ GDP complex is released from the 40S ribosomal subunit. Before eIF2 can participate in another round of initiation, the bound GDP must be exchanged for GTP, a reaction catalysed by eIF2B. Because translation of all eukaryotic mRNAs begins with tRNA i Met , changes in eIF2B activity alter global rates of protein synthesis [45] .
Unlike many GEFs, eIF2B is a heteropentameric complex, with subunits referred to using the Greek letters α-ε. The largest of the five subunits, eIF2Bε, is the catalytic subunit [46, 47] . In recent studies, we have shown that the translation of the mRNA encoding eIF2Bε is up-regulated during recovery from a single bout of resistance exercise, an effect that is blocked by the TORC1-selective inhibitor, rapamycin [48] . Expression of the other four subunits of eIF2B is unaffected by either exercise or rapamycin. Thus resistance exercise leads to a preferential increase in the expression of the catalytic subunit of eIF2B, resulting in increased eIF2B activity and protein synthesis.
Regulation of eIF2Bε mRNA translation by amino acids
In preliminary studies, we have examined the regulation of eIF2Bε mRNA translation by leucine in Rat2 cells (N. Kubica, J.L. Crispino, J.W. Gallagher, S.R. Kimball and L.S. Jefferson, unpublished work). In these studies, we found that leucine addition to leucine-deprived cells causes a redistribution of the eIF2Bε mRNA from an untranslated, non-polysomal fraction into polysomes, leading to increased incorporation of [ 35 S]methionine into eIF2Bε protein. The shift of eIF2Bε mRNA into polysomes and increased synthesis of eIF2Bε protein are both prevented by pretreatment with rapamycin, suggesting that activation of TORC1 is required for the increase. This idea is supported by the observation that exogenous expression of Rheb also leads to increased incorporation of eIF2Bε mRNA into polysomes, even in serum-deprived cells. The results of these studies suggest that activation of TORC1 is sufficient to promote increased translation of eIF2Bε mRNA.
Summary
Activation of TORC1 is an important contributor to the nutrient-induced increase in muscle protein synthesis. However, the mechanisms through which nutrients, and in particular amino acids, act to stimulate TORC1 activity are in general still poorly defined. The deficit in our understanding may in part be attributed to the numerous, and varied, mechanisms through which TORC1 signalling can be altered. Thus TORC1 signalling is regulated by a number of activating and inhibiting inputs from several upstream signalling pathways. In addition, recent studies have implicated novel signalling pathways {e.g. MAP4K3 (mitogen-activated protein kinase kinase kinase kinase 3) [49] } as potentially being involved in nutrient signalling to TORC1. Signalling from TORC1 to protein synthesis is also complicated, with several direct and indirect TORC1 substrates potentially contributing to changes in mRNA translation. Finally, although many studies focus on the rapid changes in mRNA translation associated with TORC1 activation, alterations in expression of translation initiation and elongation factors as well as increases in ribosome biogenesis are relatively unexplored consequences of longer-term and/or repeated activation of TORC1.
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